Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Sai Life Sciences Ltd (SAILIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544306 NSE: SAILIFE Pharmaceuticals & Drugs | Small Cap | Sai Life Sciences Share Price

₹1,456.35 -16.85 (-1.14%)

As on 21-Aug'26 16:59

Sai Life Sciences Ltd (SAILIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544306 NSE: SAILIFE Pharmaceuticals & Drugs | Small Cap | Sai Life Sciences Share Price

₹1,456.35 -16.85 (-1.14%)

As on 21-Aug'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹30,920 Cr.
Current Price
₹1,456.4
52-Week Low / High
₹786 / 1,482
TTM EPS
₹16.7
TTM Sales
₹2,217 Cr.
Book Value per Share
₹121.5
P/E Ratio
87.23
Higher than its 5-year historical median
Industry PE
53.2
Price to Book (P/B)
11.99
Higher than its 5-year historical median
Price to Sales (P/S)
13.95
Higher than its 5-year historical median
EV/EBITDA
46.16
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
10.97%
Outperforms industry median
Return on Capital Employed (ROCE)
15.12%
Outperforms industry median
Return on Assets (ROA)
6.33%
Operating Profit Margin
24%
Net Profit Margin
10.56%
Gross Profit Margin
21.8%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
15.74%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
36.21%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
82.15%
Asset Quality
Promoter Holding
34.53%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2,558 Cr.
Equity
₹21.2 Cr.
Face Value
₹1
All Time Low / High
₹635.30 / 1482.00

Sai Life Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Very Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong
Check Price chart
Q.1 Is Sai Life Sciences Ltd a good quality company?
Sai Life Sciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Sai Life Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Sai Life Sciences Ltd vs industry peers?
Sai Life Sciences Ltd revenue CAGR is 17.75%, compared to the industry median CAGR of 5.79%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Sai Life Sciences Ltd?
Promoters hold 34.53% of the Sai Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Sai Life Sciences Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 58.13% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sai Life Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ15.8%15.8%14.1%17.4%13.1%9.2%4.7%6.6%12.6%15.1%-
Value Creation
Index ⓘ		0.40.40.30.50.2-0.2-0.6-0.40.10.1-

Growth Parameters ⓘ
Sales ⓘ4254455266957257518411,1571,4191,6422,217
Sales YoY Gr.-4.6%18.3%32.1%4.4%3.6%11.9%37.6%22.6%15.7%-
Adj EPS ⓘ2.42.82.64.34.53.10.10.74.87.716.7
YoY Gr.-15.4%-5.1%62%6.6%-31.5%-98.4%1320%574.7%61.2%-
BVPS (₹) ⓘ19.522.625.443.648.149.450.251.256.6103.8121.5
Adj Net
Profit ⓘ		33.538.737.269.674.454.20.912.584.7161354
Cash Flow from Ops. ⓘ29.218.148.6127109-25.988.4221251330-
Debt/CF from Ops. ⓘ5.311.54.922.8-24.68.53.22.80.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ16.2%17.8%25%15.7%
Adj EPS ⓘ13.9%11.2%436.5%61.2%
BVPSⓘ20.4%16.6%27.4%83.2%
Share Price - - - 57.4%

Key Financial Parameters ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		13.713.110.912.99.96.50.11.48.810.114.8
Op. Profit
Mgn % ⓘ		18.617.31925.123.421.914.914.520.32428.3
Net Profit
Mgn % ⓘ		7.98.77.11010.37.20.11.169.816
Debt to
Equity ⓘ		0.60.70.70.40.40.70.90.80.70.1-
Working Cap
Days ⓘ		272296273238265332360281229222116
Cash Conv.
Cycle ⓘ		981401469066545251432151

Valuation of Sai Life Sciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.002.672.670.010.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales4254455266957257518411,1571,4191,642
Operating Expenses ⓘ + 3463684265205555877169911,1311,250
Manufacturing Costs535462707374107128136141
Material Costs118112132189202216248409433450
Employee Cost 117135175197202204263354431486
Other Costs ⓘ 58675764779397100132174
Operating Profit ⓘ 7977100175170164125167288392
Operating Profit Margin (%) 18.6%17.3%19.0%25.1%23.4%21.8%14.8%14.4%20.3%23.9%
Other Income ⓘ + 41976182728282937
Exceptional Items ⓘ 0000000000
Interest ⓘ 13121724213251748172
Depreciation ⓘ 2021274452728088107126
Profit Before Tax ⓘ 496362112114882233129232
Tax ⓘ 151621393422783458
Profit After Tax 344742738065162495173
PAT Margin (%) 8.1%10.6%7.9%10.5%11.1%8.7%1.9%2.1%6.7%10.6%
Adjusted EPS (₹)2.53.42.94.54.93.80.91.05.48.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2723163607137888608829031,0012,162
Share Capital ⓘ 14141416161818181821
Reserves ⓘ 2583023466977728438648859832,142
Debt +135189216226281604701633652129
Long Term Debt39706877602462972612770
Short Term Debt96119149149222358404372374129
Minority Interest0000000000
Trade Payables624897108137144193197136333
Others Liabilities ⓘ 1259794165183207329408499573
Total Liabilities ⓘ 5946517681,2121,3891,8162,1062,1412,2873,197

Fixed Assets

Net Fixed Assets ⓘ +2032723073736177028589231,0741,378
Gross Block3152933554897849301,1251,3271,5261,944
Accumulated Depreciation1122148115167227267404452567
CWIP ⓘ 891411679192189151107124
Investments ⓘ 00002263648080114
Inventories37447344437312613886118
Trade Receivables179230262234269203237277259353
Cash Equivalents 181315247937012480152458
Others Assets ⓘ 1508297198266512510492529652
Total Assets ⓘ 5946517681,2121,3891,8162,1062,1412,2873,197
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 291849127109-2688221251330
PBT ⓘ 496362112114882233129232
Adjustment ⓘ 3027491186989110154186220
Changes in Working Capital ⓘ -40-53-52-75-55-186-3639-51-100
Tax Paid ⓘ -10-20-11-28-19-17-8-4-13-21
Cash Flow From Investing Activity ⓘ + -30-69-62-158-259-279-95-111-190-565
Capex -26-71-59-158-247-240-198-66-179-363
Net Investments -40000099-3795-2
Others ⓘ 02-3-0-12-404-9-107-200
Cash Flow From Financing Activity ⓘ + 154512268-130481-190-85314
Net Proceeds from Shares ⓘ 2002275113211,012
Net Proceeds from Borrowing ⓘ -934-530-22195142-238-336
Interest Paid ⓘ -11-12-14-23-22-31-43-72-79-71
Dividend Paid ⓘ -0000000000
Others ⓘ 162330-1542139-21-97-15-290
Net Cash Flow ⓘ 14-6-1237-152-275-80-2480
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)14.0215.9812.3313.5910.687.931.82.7210.0110.97
ROCE (%)15.7815.814.1117.3713.119.24.666.5812.6115.12
Asset Turnover Ratio0.790.710.740.70.560.470.430.550.640.6
PAT to CFO Conversion(x)0.850.381.171.741.36-0.45.59.212.641.91
Working Capital Days
Receivable Days129167.50170.40130126.60114.7095.408168.8067.90
Inventory Days3233.2040.6030.802228.2043.2041.6028.8022.70
Payable Days170.90179.80200.40198221237.50247.90174.30140.40190.10

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sai Life Sciences Ltd FAQs

The current trading price of Sai Life Sciences on 21-Aug-2026 16:59 is ₹1,456.4.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Aug-2026 the market cap of Sai Life Sciences stood at ₹30,920.3 Cr

The latest P/E ratio of Sai Life Sciences as of 20-Aug-2026 is 87.23.

The latest P/B ratio of Sai Life Sciences as of 20-Aug-2026 is 11.99.

The 52-week high of Sai Life Sciences is ₹1,482 and the 52-week low is ₹786.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sai Life Sciences is ₹2,217 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sai Life Sciences Ltd is a good quality company.

The key valuation ratios of Sai Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sai Life Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Sai Life Sciences Ltd

Sai Life Sciences is a fully integrated, science-led contract research, development, and manufacturing organization (CRDMO) focused on small molecule new chemical entities (NCEs). It serves global pharmaceutical and biotechnology companies with customized solutions that accelerate the journey of molecules from discovery to the market for a healthier tomorrow.

The company operates a differentiated global delivery model - with discovery and development laboratories near key innovation hubs in the US and UK, and large-scale R&D and manufacturing facilities in India. This structure allows it to work closely with customers during development while seamlessly transferring technologies for cost-efficient commercial-scale manufacturing in India. Its business development teams, based in the US, UK, Europe, and India, strengthen client engagement and drive long-term partnerships.

Sai Life Sciences, an innovator-focused CRDMO, is the only entity of scale in India to possess both CRO and CDMO capabilities for small molecules. With a unique global delivery model, the company acts as a one-stop solution to accelerate the discovery, development, and commercialization for small molecule new chemical entities (NCE) for innovator pharmaceutical and biotech companies. The Company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms across the globe.

Business area of the company

The company is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. It provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms. 

Awards, accreditations and recognitions

  • 2020: Awarded the ‘Risk Mitigation Award’ by Institute of Supply Chain Management Pvt. Ltd. (ISCM) at the 2nd IPLA, 2020. 
  • 2020: Awarded the ‘Best SRM Initiative of the Year Award’ by Institute of Supply Chain Management Pvt. Ltd at the 2nd IPLA, 2020. 
  • 2020: Unit IV Bidar facility was awarded the ‘21st National Award for Excellence in Energy Management 2020’ for recognition as an ‘Energy Efficient Unit’ by the Confederation of Indian Industry at the National Award for Excellence in Energy Management, 2020. 
  • 2020: Awarded the ‘Golden Peacock National Quality Award, 2020’. 
  • 2020: Awarded a ‘Certificate of Excellence’ for securing a ‘5-Star Rating for Excellence in EHS Practices’ by the Confederation of Indian Industry at the CII-SR-EHS Excellence Awards for the year 2020.
  • 2021: Awarded the ‘Excellence in Practice Award for Change Management- A Paradigm Shift in Effective Learning’ by the Association for Talent Development. 
  • 2021: Awarded gold in ‘Best Advance in Learning Technology Implementation’ by the Brandon Hall Group at the HCM Excellence Awards, 2021.
  • 2021: Awarded the ‘Excellence in Practice Award for Learning Technologies- GURUKUL’ by the Association for Talent Development.
  • 2021: Awarded ‘The Resilient Procurement Strategy’ by the Institute of Supply Change Management at the India Procurement Leadership Awards - 2021.
  • 2021: Unit IV Bidar facility was awarded the ‘22nd National Award for Excellence in Energy Management 2021’ for recognition as an ‘Energy Efficient Unit’ by the Confederation of Indian Industry at the National Award for Excellence in Energy Management, 2021.
  • 2021: Awarded the ‘Golden Peacock National Training Award, 2021’ by the Institute of Directors (IOD) at the Golden Peacock Awards.
  • 2022: Sai Life Science R&T Centre Hyderabad received the ‘LEED GOLD Certification’ for fulfilment of the requirements of the LEED Green Building Rating System certification by the U.S. Green Building Council & Green Business Certification Inc. in 2022. 
  • 2022: Unit IV Bidar Facility was recognized as the ‘Energy Efficient Unit’ and was awarded the ‘23rd National Award for Excellence in Energy Management 2022’ for recognition as an ‘Energy Efficient Unit’ by the Confederation of Indian Industry at the National Award for Excellence in Energy Management, 2022.
  • 2023: Awarded gold in ‘Best Advance in Content Authoring Technology’ by the Brandon Hall Group at the Technology Excellence Awards, 2023. 
  • 2023: Unit IV Bidar Facility was awarded the ‘24th National Award for Excellence in Energy Management 2023’ for recognition as an ‘Energy Efficient Unit’ by the Confederation of Indian Industry at the National Award for Excellence in Energy Management, 2023. 
  • 2023: Awarded the ‘Excellence in Digitalizing L&D’ by the Indian Society of Training and Development, Hyderabad Chapter at the L&D Award Ceremony, 2023.
  • 2025: Sai Life Sciences wins Gold at CII Southern Region Awards.
  • 2026: Sai Life Sciences recognized as Best Organization for Women (BOW) 2026 by ET Edge.
  • 2026: Sai Life Sciences laboratories achieve Green Lab Certification.

History and milestones

  • 1999: Incorporation of the company.
  • 2002: Inauguration of its R&D labs in ICICI Knowledge Park, Hyderabad. 
  • 2004: Strategic acquisitions of Prasad Drugs Limited, the current Unit III Bolarum Facility.
  • 2006: Investment by Advantium LLC in the company to set-up discovery services to expand the company’s business. Acquired Merrifield Pharma Private Limited. 
  • 2007: Acquisition of shares of the Company held by Advantium LLC by Sequoia Capital India Investments III.
  • 2008: Investment by MPM Investment Mauritius in the company.
  • 2014: Acquisition of shares of the Company held by MPM Investment Mauritius and Sequoia Capital India Investment III by Tata Capital Healthcare Fund 1.
  • 2016: Acquisition of shares of the Company held by MPM Investment Mauritius by HBM Private Equity India and subscription to shares of the company. 
  • 2019: Opened biology facility in Watertown (Greater Boston, MA) U.S.A. 
  • 2020: Launched Sai Nxt, an initiative aiming to transform the organization into a new generation CDMO Addition of cellular analysis platforms at its discovery biology facility in Cambridge, Massachusetts, USA. 
  • 2021: Opened new 75,000 sq. ft. discovery biology facility at its integrated R&D campus at Unit II Hyderabad Facility. 
  • 2022: Inauguration of the first set of new discovery chemistry labs as part of the new integrated discovery block at Unit II Hyderabad Facility. 
  • 2022: Announced the launch of BIOVIA Electronic Lab Notebook application. 
  • 2023: Inauguration of high potency API manufacturing block at Unit IV Bidar Facility. 
  • 2024: Initiated API developability & formulations (D&F) capabilities at Unit II Hyderabad.
  • 2024: Listed on the Indian bourses – NSE & BSE.
  • 2024: Production block-11 commenced for operations.
  • 2025: Certified as a Great Place To Work.
  • 2025: Opened dedicated facility for Veterinary APIs (Unit VI) in Bidar, India.
  • 2025: Became a signatory to the UN Women’s Empowerment Principles.
  • 2025: Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators.
  • 2026: Opened first facility (Med Chem Block) at new greenfield R&D campus (Unit VIII) in IKP Hyderabad.
  • 2026: Sai Life Sciences becomes first Indian CRDMO with a site powered by 100% renewable energy.

You have 41 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Address : The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: